Skip to main content
Premium Trial:

Request an Annual Quote

John Abeles, Shelly Gunn

Premium
John Abeles has joined CombiMatrix’s scientific advisory board.
 
Abeles practiced medicine in London before becoming a senior executive in Pfizer, Sterling Drug, and Revlon Health Care. He was a healthcare analyst with Kidder Peabody and later formed MedVest, a healthcare consulting firm.
 
Abeles received his medical degree as well as a degree in pharmacology from the University of Birmingham, UK. 
 
Additionally, CombiMatrix has hired Shelly Gunn as a medical director for its CombiMatrix Molecular Diagnostics unit.
 
Gunn earned her BA and Master's degrees from TrinityUniversity. She received her MD and PhD degrees from the University of Texas Health Science Center at San Antonio Graduate School of Biomedical Sciences.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.